Biofield Energy Treatment Based Test Formulation as a Novel and Efficient Approach on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells

Journal: Open Access Journal of Pharmaceutical Research PDF  

Published: 5-Jul-19 Volume: 3 Issue: 3

DOI: 10.23880/oajpr-16000180 ISSN: 2574-7797

Authors: Streicher LN, Trivedi MK, Branton A, Trivedi D, Nayak G, Gangwar M and Jana S

Citation: Streicher LN, et al. Biofield Energy Treatment Based Test Formulation as a Novel and Efficient Approach on Various Biomarkers in human Bones, Heart, Liver, Lungs, and Brain Cells. Pharm Res 2019, 3(3): 000180.

  • 10 Views
  • Downloads

Abstract

Multiple organ dysfunction syndromes (MODS) are one of the common reasons for increased mortality rate against healthcare services. The present experiment aimed to determine the impact of the Biofield Energy Treated test formulation on the function of vital organs such as bones, heart, liver, lungs, and brain using standard activity parameters in specific cell-based assays. The test formulation and cells medium was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Laura Nelson Streicher, and USA and were labeled as the Biofield Energy Treated (BT) test formulation/media. The test formulation was tested against various activities using cell line assay. The test formulation was tested for cell viability, and the results showed that the test formulation was found non-toxic against all the cell lines at the tested concentrations. Cytoprotective activity among the experimental groups showed a significant improved activity by 156.9% at 1 μg/mL in UT- medium (Med) + BT - test item/formulation (TI) group in human cardiac fibroblasts cells (HCF) cells, while 94.5% at 25.5 μg/mL in the UT-Med + BT-TI group in human hepatoma cells (HepG2), and 92.4% at 63.75 μg/mL in the BT-Med + BT-TI group as compared with the untreated test group in adenocarcinomic human alveolar basal epithelial cells (A549) cells as compared with the untreated test group. Alkaline phosphatase (ALP) activity in MG-63 cells was significantly increased by 80.2% and 93.5% at 10 and 50 μg/mL respectively in the UT-Med + BT-TI group, while in Ishikawa cells showed maximum increased ALP activity by 51.5% at 1 μg/mL in UT-Med + BT-TI group as compared to the untreated group. The percent protection of HCF (heart) cells (decreased of lactate dehydrogenase-LDH activity) was significantly increased by 156.9% and 18.3% at 1 and 10 μg/mL concentrations respectively, in UT-Med + BT-TI group, while BT-Med + UT-TI group showed increased protection by 24.5% and 17.7% at10 and 25.5 μg/mL respectively, and 67.1%, 32.2%, 47.7%, and 73.1% improved cellular protection 1, 10, 25.5, and 63.75 μg/mL respectively, in BT-Med + BT-TI group as compared to the untreated test group. Alanine amino transferase (ALT) in terms of percent protection of HepG2 (liver) cells (decreased of ALT activity) was reported by 93.1% and 64.1% at 1 μg/mL in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively as compared to the untreated group. Cellular protection of A549 (lungs) cells (increased of superoxide dismutase-SOD activity) in terms of percentage was increased by 20.6% (at 0.1 μg/mL) and 6.9% (at 10 μg/mL) in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively as compared to untreated group. Serotonin level was significantly increased by 59.3% (at 10 μg/mL), 55.6% (at 1 μg/mL), and 100.1% (at 0.1 μg/mL) in the UT-Med + BTTI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to untreated in human neuroblastoma cells (SHSY5Y). However, the relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 150.6% (at 50 μg/mL), 380.1% (at 10 μg/mL), and 148.1% (at 50 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BTTI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, test formulation would be significantly useful for multiple organ health and improve overall health of bones, heart, liver, lungs, and brain after treatment with the Biofield Energy treated test formulation (The Trivedi Effect®). As a complementary and alternative therapy, Biofield Energy approach can be used against coronary artery disease, arrhythmias, congenital heart disease, cardiomyopathy, cirrhosis, liver cancer, hemochromatosis, asthma, chronic bronchitis, cystic fibrosis, osteoporosis, etc.

Conclusion

The test formulation was tested in various group combinations with Biofield Energy Treated and untreated test formulation groups and was found safe and non-toxic using standard MTT cell viability assay against tested cell lines with more than 70% cell viability in all six cells. Cytoprotective activity against t-BHP induced cell damage was tested using human cardiac fibroblasts cells (HCF), which showed maximum restoration of cell viability by 156.9% at 1 μg/mL in UT-Med + BT-TI group, while in HepG2 cells the maximum restoration of cell viability was 94.5% at 25.5 μg/mL in the UT-Med + BT-TI group, and the test formulation in A549 cells showed maximum restoration of cell viability by 92.4% at 63.75 μg/mL in the BT-Med + BT-TI group as compared with the untreated test group. Similarly, ALP activity in MG-63 cells showed significantly increased activity by 80.2% and 93.5% at 10 and 50 μg/mL respectively, in the UT-Med + BT-TI, while 78.3% and 85.1% at 10 and 50 μg/mL respectively, in the BT-Med + UT-TI group, and 19.2%, 76.3%, and 84% improved cellular protection at 1, 10 and 50 μg/mL respectively, in the BT-Med + BT-TI group, as compared to the UT-Med + UT-TI group. Similarly, ALP activity in Ishikawa cells with maximum cellular protection was reported by 51.5% at 1 μg/mL in UT-Med + BT-TI test group as compared with the untreated test group. The LDH activity was significantly decreased and the data was presented in increased percentage cellular protection data, which showed maximum cellular protection by 156.9% at 1 μg/mL concentration in the UT-Med + BT-TI group as compared to the untreated test group. ALT activity was studied and data showed maximum improved cellular protection of HepG2 cells (decreased of ALT activity) by 93.1% and 64.1% at 1 μg/mL in UT-Med + BT-TI and BT-Med + UT-TI groups respectively, as compared with the untreated test group. SOD activity was significantly increased by 20.6% and 12.8% at 0.1 and 63.8 μg/mL respectively, in the UT-Med + BT-TI group as compared with the untreated test group. Serotonin level was significantly increased in SH-SY5Y cells by 59.3% (at 10 μg/mL), 55.6% (at 1 μg/mL), and 100.1% (at 0.1 μg/mL) in UT-Med + BT-TI, BT-Med + UTTI, and BT-Med + BT-TI groups respectively as compared with the untreated test group. However, VDR expression was tested in MG-63 cells, which showed increased RQ of VDR by 82.6% and 150.6% in the UT-Med + BT-TI group at 10 and 50 μg/mL respectively, while 132.4%, 380.1%, and 285.3% increased RQ of VDR at 1, 10, and 50 μg/mL respectively, in the BT-Med + UT-TI group, and increased RQ of VDR by 123.5% and 148.1% at 10 and 50 μg/mL respectively, in the BT-Med + BT-TI group as compared to the untreated test control group. Overall, it can be concluded that the Biofield Energy based test formulation would be the best alternative treatment strategy for improved functioning of heart, liver, bones, neuronal, and lungs parameters against any oxidative stress or damage induced by free radicals. Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders such as stroke, thromboembolic disease, congestive heart failure, congenital heart disease, peripheral artery disease, rheumatic heart disease, valvular heart disease, and venous thrombosis, etc. Besides, it would also protect against many hepatic disorders (cirrhosis, liver cancer, hemochromatosis, Wilson disease), lungs disorders (asthma, chronic bronchitis, emphysema, cystic fibrosis, and pneumonia), and many immune system related disorders. In addition, this novel test formulation can also be utilized for organ transplants (i.e., kidney, liver, and heart transplants), hormonal imbalance, aging, and various inflammatory and immune-related disease conditions like Irritable Bowel Syndrome (IBS), Asthma, Aplastic Anemia, Graves’ Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Dermatitis, Alzheimer’s Disease (AD), Diabetes, Parkinson’s Disease, Myasthenia Gravis, Ulcerative Colitis (UC), Atherosclerosis, etc. to improve overall health and Quality of Life.